Effect of microRNA-374b-5p on proliferative diabetic retinopathy
YANG Rong1, ZHU Xu1, DUAN Zhijuan1, YANG Fang2
1. The First Department of Internal Medicine, 2. The Second Department of Internal Medicine,3. The Second Department of Surgery,Yunnan Provincial Corps Hospital of Chinese People's Armed Police Force, Kunming 650111, China
Abstract：Objective To explore the effect of microRNA-374b-5p on proliferative diabetic retinopathy. Methods Based on retrospective study, the peripheral blood of patients with diabetic non-proliferative (NPDR, n=30) and proliferative (PDR, n=32) retinopathy was collected, and the contents of microRNA-374b-5p and VEGF were determined, correlation analysis was performed at the same time, miR-374b-5p was introduced into endothelial cells to detect the expression of VEGF and the changes of endothelial cells' angiogenesis ability. Results Compared with NPDR group (7.993±6.194), the expression of serum miR-374b-5p in PDR group (4.308±3.313) decreased significantly (P<0.05). Compared with the content of VEGF in NPDR group [ (35.50±21.49)pg/ml], the content of VEGF in PDR group [((74.64±26.57)pg /ml] was significantly higher, and the difference was statistically significant (P<0.05). There was a negative correlation between miR-374b-5p and VEGF (R2=0.088, P=0.019). The level of miR-374b-5p in serum of PDR patients decreased and VEGF increased, which was negatively correlated with each other, while miR-374b-5p could inhibit the expression of VEGF mRNA and protein, and inhibit the angiogenesis ability of endothelial cells. Conclusions The decline of miR-374b-5 in the progress of PDR leads to a decline in its ability to resist the increase of VEGF expression, and induces an increase in endothelial cell angiogenesis, thereby promoting the occurrence and development of PDR.
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults [J]. JAMA, 2013, 310(9): 948-959.
[2]
Song P, Yu J, Chan K Y, et al. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis [J]. J Glob Health, 2018, 8(1):10803.
Gong Q, Xie J, Liu Y, et al. Differentially expressed microRNAs in the development of early diabetic retinopathy [J]. J Diabetes Res, 2017, 2017: 4727942.
[6]
Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the expert committee on the diagnosis and classification of diabetes mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization [J]. Diabetes Res Clin Pract, 1999, 44(1): 21-26.
[7]
Chobanian A V, Bakris G L, Black H R, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure [J]. Hypertension, 2003, 42(6): 1206-1252.
Li E H, Huang Q Z, Li G C, et al. Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene [J]. Biosci Rep, 2017, 37(2):45-56.
[12]
Mcarthur K, Feng B, Wu Y, et al. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy [J]. Diabetes, 2011, 60(4): 1314-1323.
[13]
Bartel D P. MicroRNAs: target recognition and regulatory functions [J]. Cell, 2009, 136(2): 215-233.
[14]
Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications [J]. J Cardiovasc Transl Res, 2012, 5(4): 413-422.
[15]
Singer M A, Kermany D S, Waters J, et al. Diabetic macular edema: it is more than just VEGF [J]. F1000 Res, 2016, 1:5.
2023, Vol. 34 
